Guidant Carotid Stent Study Will Enroll 400 High-Risk Patients Into Single Arm
This article was originally published in The Gray Sheet
Executive Summary
Guidant's Acculink for Revascularization of Carotids in High-Risk Patients (ARCHeR) trial, announced May 16, may represent a quicker but more restricted road to approval for the company's carotid artery stent.
You may also be interested in...
Boston Scientific Embol-X Buy Readies Firm For Carotid Stent Race
Boston Scientific's acquisition of embolic protection technology developed by Embol-X may help level the playing field with competitors Guidant and Johnson & Johnson in the race to bring carotid stent technology to market.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.